WO2008024626A3 - Bioresorbable stent with extended in vivo release of anti-restenotic agent - Google Patents

Bioresorbable stent with extended in vivo release of anti-restenotic agent Download PDF

Info

Publication number
WO2008024626A3
WO2008024626A3 PCT/US2007/075504 US2007075504W WO2008024626A3 WO 2008024626 A3 WO2008024626 A3 WO 2008024626A3 US 2007075504 W US2007075504 W US 2007075504W WO 2008024626 A3 WO2008024626 A3 WO 2008024626A3
Authority
WO
WIPO (PCT)
Prior art keywords
stents
vivo
extended
restenotic agent
stent
Prior art date
Application number
PCT/US2007/075504
Other languages
French (fr)
Other versions
WO2008024626A2 (en
Inventor
Stephen H Diaz
John F Shanley
Theodore L Parker
Frank Litvack
Original Assignee
Innovational Holdings Llc
Stephen H Diaz
John F Shanley
Theodore L Parker
Frank Litvack
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovational Holdings Llc, Stephen H Diaz, John F Shanley, Theodore L Parker, Frank Litvack filed Critical Innovational Holdings Llc
Publication of WO2008024626A2 publication Critical patent/WO2008024626A2/en
Publication of WO2008024626A3 publication Critical patent/WO2008024626A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A61L2300/604—Biodegradation

Abstract

A method for decreasing the level of restenosis following a stent placement medical intervention involves the continuous administration of a dose of an anti- restenotic agent, such as paclitaxel, from the stent to vascular tissue in need of treatment in a controlled and extended drug release profile for a period of at least 60 days in vivo. The in vivo release profile is determined by in vivo animal experiments involving implanting a series of stents in animals, explanting the stents from the animals at selected time points, and extracting remaining drug from the explanted stents.
PCT/US2007/075504 2006-08-21 2007-08-08 Bioresorbable stent with extended in vivo release of anti-restenotic agent WO2008024626A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83938706P 2006-08-21 2006-08-21
US60/839,387 2006-08-21

Publications (2)

Publication Number Publication Date
WO2008024626A2 WO2008024626A2 (en) 2008-02-28
WO2008024626A3 true WO2008024626A3 (en) 2008-10-30

Family

ID=39107522

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/075504 WO2008024626A2 (en) 2006-08-21 2007-08-08 Bioresorbable stent with extended in vivo release of anti-restenotic agent

Country Status (1)

Country Link
WO (1) WO2008024626A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
SG192523A1 (en) 2008-04-17 2013-08-30 Micell Technologies Inc Stents having bioabsorbable layers
DE102008040356A1 (en) * 2008-07-11 2010-01-14 Biotronik Vi Patent Ag Stent with biodegradable stent struts and drug depots
CN102159257B (en) 2008-07-17 2015-11-25 米歇尔技术公司 Drug delivery medical device
AU2010200316A1 (en) * 2009-01-30 2010-08-19 Cordis Corporation Reservoir Eluting Stent
CA2757276C (en) 2009-04-01 2017-06-06 Micell Technologies, Inc. Coated stents
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc Drug delivery medical device
EP2531140B1 (en) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
CA2797110C (en) 2010-04-22 2020-07-21 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
WO2012009684A2 (en) 2010-07-16 2012-01-19 Micell Technologies, Inc. Drug delivery medical device
CA2841360A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
WO2014165264A1 (en) * 2013-03-12 2014-10-09 Micell Technologies, Inc. Bioabsorbable biomedical implants
EP2996629B1 (en) 2013-05-15 2021-09-22 Micell Technologies, Inc. Bioabsorbable biomedical implants

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040204756A1 (en) * 2004-02-11 2004-10-14 Diaz Stephen Hunter Absorbent article with improved liquid acquisition capacity
US20040220660A1 (en) * 2001-02-05 2004-11-04 Shanley John F. Bioresorbable stent with beneficial agent reservoirs
WO2006044989A1 (en) * 2004-10-18 2006-04-27 Avantec Vascular Corporation Devices and methods for delivery of pimecrolimus and other therapeutic agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220660A1 (en) * 2001-02-05 2004-11-04 Shanley John F. Bioresorbable stent with beneficial agent reservoirs
US20040204756A1 (en) * 2004-02-11 2004-10-14 Diaz Stephen Hunter Absorbent article with improved liquid acquisition capacity
WO2006044989A1 (en) * 2004-10-18 2006-04-27 Avantec Vascular Corporation Devices and methods for delivery of pimecrolimus and other therapeutic agents

Also Published As

Publication number Publication date
WO2008024626A2 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
WO2008024626A3 (en) Bioresorbable stent with extended in vivo release of anti-restenotic agent
WO2004110302A3 (en) Methods of delivering anti-restenotic agents from a stent
Ma et al. Paclitaxel/sirolimus combination coated drug-eluting stent: in vitro and in vivo drug release studies
WO2007092833A3 (en) Drug delivery stent with extended in vivo drug release
WO2010039641A3 (en) Long term drug delivery devices with polyurethane-based polymers and their manufacture
EP2229919A3 (en) Bioresorbable stent with beneficial agent reservoirs
US20060212108A1 (en) System for treatment of extensive obliterative vascular diseases
MX2009005405A (en) Intraocular drug delivery systems.
WO2009129509A3 (en) Methods and compositions for treating post-operative pain comprising a local anesthetic
WO2008057344A3 (en) Coated surgical mesh
EP1723976A3 (en) Intraluminal medical devices in combination with therapeutic agents
WO2008073670A3 (en) Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
ATE441381T1 (en) DEVICE FOR STORING ROLLED DENTURES
MX2010007571A (en) Rapamycin reservoir eluting stent.
EP1591108A3 (en) Solution formulations of sirolimus and its analogs for CAD treatment
WO2006108065A3 (en) Degradable implantable medical devices
CN102048602B (en) Preparation method of meshy degradable blood vessel stent
ATE526048T1 (en) COATED BIODEGRADABLE METALLIC IMPLANT
JP2016516780A5 (en)
EP2042202A3 (en) Local vascular delivery of mTor inhibitors in combination with peroxisome proliferators-activated receptor stimulators
DE602005022515D1 (en) Local, vascular administration of etoposide in combination with rapamycin for the prevention of restenosis after vascular injury
RU2006126779A (en) PHARMACEUTICAL COMPOSITIONS
UA105502C2 (en) Implantable device for the delivery of octreotide and methods of use thereof
EP1974758A3 (en) Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, AAA and stroke
Yue et al. Effectiveness of biodegradable magnesium alloy stents in coronary artery and femoral artery

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07840786

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07840786

Country of ref document: EP

Kind code of ref document: A2